BioCardia Regains Compliance with Nasdaq Listing Requirements
BioCardia (Nasdaq: BCDA), a cardiovascular and pulmonary therapeutics company, has successfully regained compliance with Nasdaq Capital Market's Listing Requirements. The company received official confirmation from Nasdaq on October 1, 2025, verifying its compliance with Listing Rule 5550(b)(1), known as the Equity Rule.
This achievement follows BioCardia's efforts to strengthen its balance sheet through capital raising initiatives, which will support the continued development of its therapeutic candidates and advancement of approved products. The company's securities will maintain their listing on the Nasdaq Capital Market under the symbol "BCDA".
BioCardia (Nasdaq: BCDA), un'azienda di terapie cardiovascolari e polmonari, ha nuovamente adeguato la propria normativa alle condizioni di Listing della Nasdaq Capital Market. L'azienda ha ricevuto conferma ufficiale da Nasdaq il 1 ottobre 2025, verificando la conformità al Listing Rule 5550(b)(1), noto come Equity Rule.
Questo risultato segue gli sforzi di BioCardia per rafforzare la sua situazione patrimoniale attraverso iniziative di raccolta capitale, che sosterranno lo sviluppo continuo dei suoi candidati terapeutici e l'avanzamento dei prodotti approvati. Le securities della società manterranno la loro ammissione al Nasdaq Capital Market con il simbolo "BCDA".
BioCardia (Nasdaq: BCDA), una empresa de terapias cardiovasculares y pulmonares, ha recuperado con éxito el cumplimiento de los Requisitos de Listing del Nasdaq Capital Market. La compañía recibió la confirmación oficial de Nasdaq el 1 de octubre de 2025, verificando su cumplimiento con la Regla de Equidad 5550(b)(1).
Este logro sigue a los esfuerzos de BioCardia para fortalecer su balance a través de iniciativas de levantamiento de capital, que apoyarán el desarrollo continuo de sus candidatos terapéuticos y el avance de los productos aprobados. Las securities de la empresa permanecerán listadas en Nasdaq Capital Market bajo el símbolo "BCDA".
BioCardia(Nasdaq: BCDA)은 심혈관 및 호흡기 치료제를 개발하는 회사로, Nasdaq Capital Market의 상장 요건에 성공적으로 재규정을 충족했습니다. 회사는 2025년 10월 1일에 Nasdaq로부터 상장규정 5550(b)(1), 즉 Equity Rule의 준수를 확인하는 공식 확인서를 받았습니다.
이 성과는 회사의 자본조달 이니셔티브를 통한 대차대조표 강화를 통해 가능해졌으며, 이는 치료 후보의 개발 지속 및 승인된 제품의 진행을 지원할 것입니다. 회사의 주식은 BCDA라는 심볼로 Nasdaq Capital Market에 상장되어 유지될 것입니다.
BioCardia (Nasdaq : BCDA), une société de thérapies cardiovasculaires et pulmonaires, a rétabli avec succès sa conformité aux exigences de cotation du Nasdaq Capital Market. L'entreprise a reçu la confirmation officielle de Nasdaq le 1 octobre 2025, vérifiant sa conformité à la Règle d'Équité 5550(b)(1).
Cet exercice fait suite aux efforts de BioCardia pour renforcer son bilan par le biais d'initiatives de levée de capitaux, qui soutiendront le développement continu de ses candidats thérapeutiques et l'avancement de produits approuvés. Les titres de la société resteront cotés sur le Nasdaq Capital Market sous le symbole "BCDA".
BioCardia (Nasdaq: BCDA), ein Unternehmen für kardiovaskuläre und pulmonale Therapien, hat die Einhaltung der Listing-Anforderungen des Nasdaq Capital Market erfolgreich wiederhergestellt. Das Unternehmen erhielt am 1. Oktober 2025 die offizielle Bestätigung von Nasdaq, die die Einhaltung der Listing Rule 5550(b)(1), bekannt als die Equity Rule, bestätigt.
Dieser Erfolg folgt auf BioCardias Bemühungen, seine Bilanz durch Kapitalbeschaffungsinitiativen zu stärken, was die fortgesetzte Entwicklung seiner therapeutischen Kandidaten und den Fortschritt zugelassener Produkte unterstützen wird. Die Wertpapiere des Unternehmens werden weiterhin unter dem Symbol "BCDA" am Nasdaq Capital Market notiert.
BioCardia (ناسداك: BCDA)، شركة متخصصة في علاجات القلب والرئة، أكملت بنجاح الامتثال لمتطلبات الإدراج في سوق Nasdaq Capital Market. تلقت الشركة تأكيداً رسمياً من Nasdaq في 1 أكتوبر 2025، يؤكد امتثالها لقاعدة الإدراج 5550(b)(1)، المعروفة باسم قاعدة حقوق الملكية.
يأتي هذا الإنجاز بعد جهود BioCardia لتعزيز ميزانيتها من خلال مبادرات جمع رأس المال، والتي ستدعم التطوير المستمر للمرشحين العلاجيين وتقدم المنتجات المعتمدة. ستظل أوراق الشركة مدرجة في Nasdaq Capital Market تحت الرمز "BCDA".
BioCardia（纳斯达克代码：BCDA），一家心血管与肺部治疗公司，已成功重新符合纳斯达克资本市场的上市要求。该公司于2025年10月1日收到纳斯达克的正式确认，确认其符合上市规则5550(b)(1)，即股权规则。
这一成就源自BioCardia通过增资举措来强化资产负债表的努力，这将支持其治疗候选药的持续开发以及已获批产品的推进。公司的证券将在符号“BCDA”的情况下继续在纳斯达克资本市场上市。
- Successfully regained Nasdaq listing compliance
- Raised new capital to strengthen balance sheet
- Secured funding for therapeutic development and product advancement
- Previous non-compliance with Nasdaq listing requirements indicates past financial challenges
SUNNYVALE, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has regained compliance with the Nasdaq Capital Market’s Listing Requirements (the “Listing Requirements”). This confirmation follows the Company’s successful efforts to improve its balance sheet, including raising new capital to continue development of its therapeutic candidates and advance its approved products.
Specifically, on October 1, 2025, BioCardia received written notice (the “Notice”) from Nasdaq confirming that the Nasdaq Staff has determined the Company complies with Listing Rule 5550(b)(1), (the “Equity Rule”). Accordingly, the Company’s securities will continue to be listed on the Nasdaq Capital Market under the symbol “BCDA.”
About BioCardia:
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms, and soon the Heart3DTM fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information visit www.biocardia.com.
Forward Looking Statements
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the Company’s continued ability to raise capital to continue development of its therapeutic candidates and advance its approved products and maintain compliance with Listing Requirements. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release as a result of one or more risk factors. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 26, 2025, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Media Contact: Miranda Peto, Investor Relations Email: mpeto@biocardia.com Phone: 650-226-0120 Investor Contact: David McClung, Chief Financial Officer Email: investors@biocardia.com Phone: 650-226-0120
FAQ
What did BioCardia (BCDA) announce regarding Nasdaq compliance on October 2, 2025?
How did BioCardia (BCDA) regain Nasdaq compliance?
Will BioCardia (BCDA) continue trading on Nasdaq?
What is BioCardia's (BCDA) main business focus?
